Tyra Biosciences, Inc.
TYRA
$25.38
$0.361.42%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 37.28% | 23.85% | 10.13% | 26.54% | 29.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.80% | 31.86% | 22.77% | 15.17% | 33.66% |
| Operating Income | -55.80% | -31.86% | -22.77% | -15.17% | -33.66% |
| Income Before Tax | -62.14% | -39.64% | -32.31% | -24.37% | -50.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -62.14% | -39.64% | -32.31% | -24.37% | -50.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -62.14% | -39.64% | -32.31% | -24.37% | -50.24% |
| EBIT | -55.80% | -31.86% | -22.77% | -15.17% | -33.66% |
| EBITDA | -56.06% | -32.02% | -22.92% | -15.23% | -33.78% |
| EPS Basic | -46.33% | -34.19% | -30.60% | -22.70% | -47.99% |
| Normalized Basic EPS | -46.32% | -34.17% | -30.60% | -22.71% | -48.04% |
| EPS Diluted | -46.33% | -34.19% | -30.60% | -22.70% | -47.99% |
| Normalized Diluted EPS | -46.32% | -34.17% | -30.60% | -22.71% | -48.04% |
| Average Basic Shares Outstanding | 10.81% | 4.06% | 1.31% | 1.35% | 1.50% |
| Average Diluted Shares Outstanding | 10.81% | 4.06% | 1.31% | 1.35% | 1.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |